Nitisinone attenuates cartilage degeneration and subchondral osteoclastogenesis in osteoarthritis and concomitantly inhibits the cGAS/STING/NF-κB pathway.
Eur J Pharmacol
; 965: 176326, 2024 Feb 15.
Article
em En
| MEDLINE
| ID: mdl-38220141
ABSTRACT
Osteoarthritis (OA) is a chronic degenerative joint disease characterized by cartilage degeneration and subchondral bone remodelling. Currently, conservative treatment strategies cannot effectively alleviate the progression of OA. In this study, we used computer network analysis to show that Nitisinone (NTBC) is closely related to extracellular matrix degradation in OA and mainly interferes with the TNF-α signaling pathway. NTBC is an orphan drug used to treat hereditary type I tyrosinemia by altering phenylalanine/tyrosine metabolic flow. In this study, we found that NTBC effectively reduced chondrocyte inflammation and extracellular matrix degradation induced by TNF-α. Mechanistically, NTBC inhibited the cGAS/STING signaling pathway and reduced activation of the STING-dependent NF-κB pathway to alleviate inflammation. In addition, NTBC inhibited osteoclastogenesis and delayed the occurrence of subchondral bone remodelling. In mice with ACLT-induced osteoarthritis, intra-articular injection of NTBC significantly reduced cartilage degradation and subchondral bone remodelling. NTBC showed impressive therapeutic efficacy as a potential pharmaceutical intervention for the treatment of OA.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Osteoartrite
/
Cartilagem Articular
/
Cicloexanonas
/
Nitrobenzoatos
Limite:
Animals
Idioma:
En
Revista:
Eur J Pharmacol
/
Eur. j. pharmacol
/
European journal of pharmacology
Ano de publicação:
2024
Tipo de documento:
Article